MedPath

Evaluation of Gabapentin as a drug that helps in postoperative pain management of Knee Surgery

Not Applicable
Conditions
Sprain and strain involving (anterior) (posterior) cruciate ligament of knee
M00-M99
Registration Number
RBR-3zvc3s
Lead Sponsor
Instituto de Ortopedia e Traumatologia de Joinville
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Patients of both genders, aged between 18 and 50 years; with single lesion of the unilateral Anterior Cruciate Ligament; who undergo surgical treatment of a single lesion of the Anterior Cruciate Ligament.

Exclusion Criteria

Patients who present allergy to Gabapentin, Tramadol, Dipyrone or Nimesulide (prior or during the study); Renal or Hepatic Insufficiency; patients with recent previous use of anticonvulsants, opioids, or antidepressant agents; or who are being treated with cimetidine or antacids for any reason; associated chondral lesion; injury of another associated ligament; associated meniscal injury; diabetes mellitus; fibromyalgia; chronic pain; depressive disorder, bipolar disorder, generalized anxiety disorder; history of illegal substance use or alcohol abuse; non-literate patients and those who do not agree to sign the Informed Consent Form.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Patients receiving Gabapentin in the Multimodal Analgesia scheme (Gabapentin Group) will consume fewer opioids in the recent postoperative period than patients who received Placebo in the same Multimodal Analgesia scheme (Placebo Group).<br>
Secondary Outcome Measures
NameTimeMethod
1. Patients in the Gabapentin Group will present lower scores on the Pain Scales compared to those in the Placebo Group.<br>2. Gabapentin Group patients will have fewer adverse effects than Placebo Group patients.
© Copyright 2025. All Rights Reserved by MedPath